Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

PDGFRB (platelet-derived growth factor receptor, beta polypeptide)

Identity

Other namesBC032224
J03278
M21616
JTK12
PDGFR
CD140B
PDGFR1
PDGF-R-beta
HGNC (Hugo) PDGFRB
LocusID (NCBI) 5159
Location 5q32
Location_base_pair Starts at 149493402 and ends at 149535422 bp from pter ( according to hg19-Feb_2009)  [Mapping]
Local_order MXI1 (MAX-interacting protein 1) is more telomeric. XPNPEP1 (X-prolylaminopeptidase 1) is more telomeric.
 
  Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics

DNA/RNA

 
  Genomic structure of PDGFRB. Black boxes indicate exons, small ones indicate untranslated exons.
Description 23 exons spanning 149.5 Mb on 5q31-q32. Transcription is from telomere to centromere.
Transcription 1 transcript in RefSeq encoding NP_002600. 1 transcript in EnsEMBL encoding ENSP00000261799.

Protein

Note PDGFRB; Beta platelet-derived growth factor receptor [Precursor]
 
  Schematic representation of PDGFRB. Ig-like domains: extracellular immunoglobulin-like domains involved in protein-ligand interaction, TM: transmembrane domain, Split-TK domain: RTK class III cytoplasmic kinase domain with an insertion of 70 to 100 hydrophilic residues.
Description Beta platelet-derived growth factor receptor precursor (PDGF-R-beta) (CD140b antigen).
Localisation Type I membrane protein.
Function is receptor that binds specifically to PDGFB and has a tyrosine-protein kinase activity. Is a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor (PDGF) family. The PDGFR/PDGF system includes two receptors (PDGFRA and PDGFRB) and four ligands (, B, C and D). The receptors PDGFRA and PDGFRB are related in sequence and both are members of the class III subtype of receptor tyrosine kinases (RTKs). Other class III RTKs are CSF1R, KIT and FLT3. Mature PDGFRB consist of 1067 amino acids and can bind strongly to PDGF-BB and -DD homodimers, but weakly to AB heterodimers and not to PDGF-AA homodimer. The different ligands seem to induce different signals.
Homology PDGFRB presents homology in several species. It also belongs to GROWTH FACTOR RECEPTOR PRECURSOR EC_2.7.1.112 TYROSINE KINASE protein family.

Mutations

Germinal See SNPs at EnsEMBL (http://www.ensembl.org/Homo_sapiens/genesnpview?db=core&gene=ENSG00000113721).

Implicated in

Note Some rare gene fusions involving PDGFRB have been described in several patients with chronic myeloproliferative disorders (CMPD), myelodysplastic/myeloproliferative syndromes (MDS/MPD) and AML, often associated with eosinophilia and splenomegaly. Transformation to acute leukemia has been observed in a minor proportion of cases. Some of them respond to imatinib mesylate.
  
Entity t(1;5)(q23;q33)
Disease described in an 11 month old girl with myelodysplastic/myeloproliferative syndrome with eosinophilia
Prognosis bad
Cytogenetics t(1;5)(q23;q33)
Hybrid/Mutated Gene 5' PDE4DIP-PDGFRB 3'
Abnormal Protein PDE4DIP-PDGFRB
  
Entity t(1;3;5)(p36;p21;q33)
Note PDGFRB fusion partner unpublished. Translocation described in a patient with a chronic myeloproliferative disorder
Disease CMPD
Cytogenetics t(1;3;5)(p36;p21;q33)
Hybrid/Mutated Gene unidentified
Abnormal Protein unidentified.
  
Entity t(2;12;5)(q37;q22;q33)
Note PDGFRB fusion partner unpublished.
Disease Translocation described in a patient with a myelodysplastic syndrome
Cytogenetics t(2;12;5)(q37;q22;q33)
Hybrid/Mutated Gene unidentified.
Abnormal Protein unidentified.
  
Entity t(3;5)(p21;q31)
Note PDGFRB fusion partner unpublished.
Disease Translocation described in a patient with an atypical CML
Cytogenetics t(3;5)(p21;q31)
Hybrid/Mutated Gene unidentified.
Abnormal Protein unidentified.
  
Entity t(5;7)(q33;q11.2)
Disease Described in two patients with CMML/eosinophilia and CMML
Prognosis unknown.
Cytogenetics t(5;7)(q33;q11.2)
Hybrid/Mutated Gene 5' HIP1-PDGFRB 3'
Abnormal Protein HIP1-PDGFRB
  
Entity t(5;10)(q33;q22)
Disease Described in five cases with atypical CML.
Prognosis good, imatinib mesylate responsive disease.
Cytogenetics t(5;10)(q33;q22)
Hybrid/Mutated Gene 5' H4-PDGFRB 3'
Abnormal Protein H4-PDGFRB
  
Entity t(5;12)(q33;p13)
Disease Associated to atypical CML, AML, chronic myelomonocytic leukaemia (CMML), chronic eosinophilic leukaemia (CEL) or unclassified myeloproliferative disorders
Prognosis Good.
Cytogenetics t(5;12)(q33;p13)
Hybrid/Mutated Gene 5' ETV6-PDGFRB 3'
Abnormal Protein ETV6-PDGFRB
  
Entity t(5;14)(q33;q32)
Disease Described in a patient with AML and a t(7;11)(p15;p15) at initial diagnosis, who relapsed with a prominent eosinophilia, hepatosplenomegaly and t(5;14) as an additional cytogenetic abnormality.
Prognosis Good.
Cytogenetics t(5;14)(q33;q32)
Hybrid/Mutated Gene 5' TRIP11-PDGFRB 3'
Abnormal Protein TRIP11-PDGFRB
  
Entity t(5;14)(q33;q24)
Disease described in a patient with a chronic myeloproliferative disorder with eosinophilia
Prognosis Good, imatinib mesylate responsive disease.
Cytogenetics t(5;14)(q33;q24)
Hybrid/Mutated Gene 5' NIN-PDGFRB 3'
Abnormal Protein NIN-PDGFRB
  
Entity t(5;14)(q31;q32)
Disease described in a patient with a chronic myeloproliferative disorder with peripheral blood monocitosis
Prognosis Good, imatinib mesylate responsive disease.
Cytogenetics t(5;14)(q31;q32)
Hybrid/Mutated Gene 5' KIAA1509-PDGFRB 3'
Abnormal Protein 5' KIAA1509-PDGFRB 3'
  
Entity t(5;15)(q33;q22)
Disease described in a patient with a chronic myeloproliferative disorder with eosinophilia
Prognosis Imatinib mesylate responsive disease but the patient described resistance was developed.
Cytogenetics t(5;15)(q33;q22)
Hybrid/Mutated Gene 5' TP53BP1-PDGFRB 3'
Abnormal Protein TP53BP1-PDGFRB
  
Entity t(5;17)(q33;p11.2)
Disease JMML/CMML
Prognosis Good.
Cytogenetics t(5;17)(q33;p11.2)
Hybrid/Mutated Gene 5' HCMOGT-PDGFRB 3' fusion described in an 18 month old boy with juvenile myelomonocytic leukemia and eosinophilia
Abnormal Protein HCMOGT-PDGFRB
  
Entity t(5;17)(q33;p13)
Disease described in a patient with chronic myelomonocitic leukemia
Prognosis unknown.
Cytogenetics t(5;17)(q33;p13)
Hybrid/Mutated Gene 5' RABEP1-PDGFRB 3'
Abnormal Protein RABEP1-PDGFRB
  

Breakpoints

 

Other Leukemias implicated (Data extracted from papers in the Atlas)

Leukemias 11q23ChildAMLID1615 11q23ID1030 11q23secondLeukID1131 t1119ELLID1029 t0812q24q22ID2057
t0814ID1050 8p11inMPDID1091 inv8p11q13ID1189 PrimarCutanALCLID2118 t0708q34p11ID1409
t0809p12q33ID1129 t0811p11p15ID1200 t0811p12p15ID1521 t0812p12p11ID1330 t0812p12q15ID1201
t0817p12q23ID1387 t0817p12q25ID1202 t0819p11q13ID1315 t0819p12q13ID1203 t0822p11q11ID1224
t0822p11q13ID1119 t0921q34q22ID1483 t68ID1090 t813ID1094 t68ID1090

External links

Nomenclature
HGNC (Hugo)PDGFRB   8804
Cards
AtlasPDGFRBID21ch5q32
Entrez_Gene (NCBI)PDGFRB  5159  platelet-derived growth factor receptor, beta polypeptide
GeneCards (Weizmann)PDGFRB
Ensembl hg19 (Hinxton)ENSG00000113721 [Gene_View]  chr5:149493402-149535422 [Contig_View]  PDGFRB [Vega]
Ensembl hg38 (Hinxton)ENSG00000113721 [Gene_View]  chr5:149493402-149535422 [Contig_View]  PDGFRB [Vega]
ICGC DataPortalENSG00000113721
cBioPortalPDGFRB
AceView (NCBI)PDGFRB
Genatlas (Paris)PDGFRB
WikiGenes5159
SOURCE (Princeton)PDGFRB
Genomic and cartography
GoldenPath hg19 (UCSC)PDGFRB  -     chr5:149493402-149535422 -  5q33.1   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)PDGFRB  -     5q33.1   [Description]    (hg38-Dec_2013)
EnsemblPDGFRB - 5q33.1 [CytoView hg19]  PDGFRB - 5q33.1 [CytoView hg38]
Mapping of homologs : NCBIPDGFRB [Mapview hg19]  PDGFRB [Mapview hg38]
OMIM131440   173410   213600   228550   615007   
Gene and transcription
Genbank (Entrez)AB209657 AI346188 AK293093 BC032224 CN268096
RefSeq transcript (Entrez)NM_002609
RefSeq genomic (Entrez)AC_000137 NC_000005 NC_018916 NG_023367 NT_029289 NW_001838953 NW_004929324
Consensus coding sequences : CCDS (NCBI)PDGFRB
Cluster EST : UnigeneHs.509067 [ NCBI ]
CGAP (NCI)Hs.509067
Alternative Splicing : Fast-db (Paris)GSHG0025173
Alternative Splicing GalleryENSG00000113721
Gene ExpressionPDGFRB [ NCBI-GEO ]     PDGFRB [ SEEK ]   PDGFRB [ MEM ]
SOURCE (Princeton)Expression in : [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP09619 (Uniprot)
NextProtP09619  [Medical]
With graphics : InterProP09619
Splice isoforms : SwissVarP09619 (Swissvar)
Catalytic activity : Enzyme2.7.10.1 [ Enzyme-Expasy ]   2.7.10.12.7.10.1 [ IntEnz-EBI ]   2.7.10.1 [ BRENDA ]   2.7.10.1 [ KEGG ]   
Domaine pattern : Prosite (Expaxy)IG_LIKE (PS50835)    PROTEIN_KINASE_ATP (PS00107)    PROTEIN_KINASE_DOM (PS50011)    PROTEIN_KINASE_TYR (PS00109)    RECEPTOR_TYR_KIN_III (PS00240)   
Domains : Interpro (EBI)Ig-like_dom    Ig-like_fold    Ig_I-set    Ig_sub    Ig_sub2    Immunoglobulin    Kinase-like_dom    PGFRB    Prot_kinase_dom    Protein_kinase_ATP_BS    Ser-Thr/Tyr_kinase_cat_dom    Tyr_kinase_AS    Tyr_kinase_cat_dom    Tyr_kinase_CSF1/PDGF_rcpt    Tyr_kinase_rcpt_3_CS   
Related proteins : CluSTrP09619
Domain families : Pfam (Sanger)I-set (PF07679)    ig (PF00047)    Pkinase_Tyr (PF07714)   
Domain families : Pfam (NCBI)pfam07679    pfam00047    pfam07714   
Domain families : Smart (EMBL)IG (SM00409)  IGc2 (SM00408)  TyrKc (SM00219)  
DMDM Disease mutations5159
Blocks (Seattle)P09619
PDB (SRS)1GQ5    1H9O    1LWP    1SHA    2L6W    2PLD    2PLE    3MJG   
PDB (PDBSum)1GQ5    1H9O    1LWP    1SHA    2L6W    2PLD    2PLE    3MJG   
PDB (IMB)1GQ5    1H9O    1LWP    1SHA    2L6W    2PLD    2PLE    3MJG   
PDB (RSDB)1GQ5    1H9O    1LWP    1SHA    2L6W    2PLD    2PLE    3MJG   
Human Protein AtlasENSG00000113721
Peptide AtlasP09619
HPRD01423
IPIIPI00015902   IPI00909967   IPI01010238   IPI00974584   IPI00984785   IPI00975732   
Protein Interaction databases
DIP (DOE-UCLA)P09619
IntAct (EBI)P09619
FunCoupENSG00000113721
BioGRIDPDGFRB
IntegromeDBPDGFRB
STRING (EMBL)PDGFRB
Ontologies - Pathways
QuickGOP09619
Ontology : AmiGOin utero embryonic development  tissue homeostasis  protein tyrosine kinase activity  platelet activating factor receptor activity  platelet-derived growth factor-activated receptor activity  platelet-derived growth factor beta-receptor activity  platelet-derived growth factor beta-receptor activity  receptor binding  platelet-derived growth factor receptor binding  protein binding  ATP binding  nucleus  cytoplasm  plasma membrane  glycosaminoglycan biosynthetic process  signal transduction  epidermal growth factor receptor signaling pathway  transforming growth factor beta receptor signaling pathway  G-protein coupled receptor signaling pathway  positive regulation of cell proliferation  fibroblast growth factor receptor signaling pathway  response to toxic substance  positive regulation of phospholipase C activity  positive regulation of phosphatidylinositol 3-kinase signaling  positive regulation of smooth muscle cell migration  positive regulation of smooth muscle cell migration  membrane  integral component of membrane  cytoplasmic membrane-bounded vesicle  apical plasma membrane  cell migration  peptidyl-tyrosine phosphorylation  protein kinase binding  adrenal gland development  positive regulation of cell migration  intrinsic component of plasma membrane  response to estradiol  positive regulation of phosphoprotein phosphatase activity  response to retinoic acid  regulation of actin cytoskeleton organization  positive regulation of collagen biosynthetic process  response to fluid shear stress  cell migration involved in vasculogenesis  metanephric mesenchymal cell migration  platelet-derived growth factor receptor-beta signaling pathway  positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway  aorta morphogenesis  cellular response to platelet-derived growth factor stimulus  vascular endothelial growth factor binding  positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway  Fc-epsilon receptor signaling pathway  wound healing  response to hydrogen peroxide  negative regulation of apoptotic process  lysosomal lumen  positive regulation of MAP kinase activity  phosphatidylinositol 3-kinase binding  positive regulation of phosphatidylinositol 3-kinase activity  innate immune response  positive regulation of mitosis  phosphatidylinositol metabolic process  protein autophosphorylation  platelet-derived growth factor receptor signaling pathway  neurotrophin TRK receptor signaling pathway  phosphatidylinositol-mediated signaling  phosphatidylinositol-mediated signaling  platelet-derived growth factor binding  platelet-derived growth factor binding  positive regulation of smooth muscle cell proliferation  positive regulation of smooth muscle cell proliferation  skeletal system morphogenesis  smooth muscle tissue development  inner ear development  regulation of peptidyl-tyrosine phosphorylation  positive regulation of chemotaxis  cardiac myofibril assembly  response to hyperoxia  cell chemotaxis  cell migration involved in coronary angiogenesis  retina vasculature development in camera-type eye  extracellular vesicular exosome  positive regulation of ERK1 and ERK2 cascade  positive regulation of ERK1 and ERK2 cascade  smooth muscle cell chemotaxis  metanephric mesenchyme development  metanephric glomerular mesangial cell proliferation involved in metanephros development  metanephric glomerular capillary formation  metanephric comma-shaped body morphogenesis  metanephric S-shaped body morphogenesis  positive regulation of calcium ion import  positive regulation of reactive oxygen species metabolic process  positive regulation of DNA biosynthetic process  
Ontology : EGO-EBIin utero embryonic development  tissue homeostasis  protein tyrosine kinase activity  platelet activating factor receptor activity  platelet-derived growth factor-activated receptor activity  platelet-derived growth factor beta-receptor activity  platelet-derived growth factor beta-receptor activity  receptor binding  platelet-derived growth factor receptor binding  protein binding  ATP binding  nucleus  cytoplasm  plasma membrane  glycosaminoglycan biosynthetic process  signal transduction  epidermal growth factor receptor signaling pathway  transforming growth factor beta receptor signaling pathway  G-protein coupled receptor signaling pathway  positive regulation of cell proliferation  fibroblast growth factor receptor signaling pathway  response to toxic substance  positive regulation of phospholipase C activity  positive regulation of phosphatidylinositol 3-kinase signaling  positive regulation of smooth muscle cell migration  positive regulation of smooth muscle cell migration  membrane  integral component of membrane  cytoplasmic membrane-bounded vesicle  apical plasma membrane  cell migration  peptidyl-tyrosine phosphorylation  protein kinase binding  adrenal gland development  positive regulation of cell migration  intrinsic component of plasma membrane  response to estradiol  positive regulation of phosphoprotein phosphatase activity  response to retinoic acid  regulation of actin cytoskeleton organization  positive regulation of collagen biosynthetic process  response to fluid shear stress  cell migration involved in vasculogenesis  metanephric mesenchymal cell migration  platelet-derived growth factor receptor-beta signaling pathway  positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway  aorta morphogenesis  cellular response to platelet-derived growth factor stimulus  vascular endothelial growth factor binding  positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway  Fc-epsilon receptor signaling pathway  wound healing  response to hydrogen peroxide  negative regulation of apoptotic process  lysosomal lumen  positive regulation of MAP kinase activity  phosphatidylinositol 3-kinase binding  positive regulation of phosphatidylinositol 3-kinase activity  innate immune response  positive regulation of mitosis  phosphatidylinositol metabolic process  protein autophosphorylation  platelet-derived growth factor receptor signaling pathway  neurotrophin TRK receptor signaling pathway  phosphatidylinositol-mediated signaling  phosphatidylinositol-mediated signaling  platelet-derived growth factor binding  platelet-derived growth factor binding  positive regulation of smooth muscle cell proliferation  positive regulation of smooth muscle cell proliferation  skeletal system morphogenesis  smooth muscle tissue development  inner ear development  regulation of peptidyl-tyrosine phosphorylation  positive regulation of chemotaxis  cardiac myofibril assembly  response to hyperoxia  cell chemotaxis  cell migration involved in coronary angiogenesis  retina vasculature development in camera-type eye  extracellular vesicular exosome  positive regulation of ERK1 and ERK2 cascade  positive regulation of ERK1 and ERK2 cascade  smooth muscle cell chemotaxis  metanephric mesenchyme development  metanephric glomerular mesangial cell proliferation involved in metanephros development  metanephric glomerular capillary formation  metanephric comma-shaped body morphogenesis  metanephric S-shaped body morphogenesis  positive regulation of calcium ion import  positive regulation of reactive oxygen species metabolic process  positive regulation of DNA biosynthetic process  
Pathways : KEGGMAPK signaling pathway    Ras signaling pathway    Rap1 signaling pathway    Calcium signaling pathway    Cytokine-cytokine receptor interaction    PI3K-Akt signaling pathway    Focal adhesion    Gap junction    Regulation of actin cytoskeleton    HTLV-I infection    Pathways in cancer    MicroRNAs in cancer    Glioma    Prostate cancer    Melanoma   
REACTOMEP09619 [protein]
REACTOME PathwaysREACT_116125 Disease [pathway]
REACTOME PathwaysREACT_6900 Immune System [pathway]
REACTOME PathwaysREACT_111102 Signal Transduction [pathway]
Protein Interaction DatabasePDGFRB
DoCM (Curated mutations)PDGFRB
Wikipedia pathwaysPDGFRB
Gene fusion - rearrangements
Rearrangement : TICdbCCDC6 [10q21.2]  -  PDGFRB [1p13.3]
Rearrangement : TICdbCCDC88C [14q32.11]  -  PDGFRB [11q21]
Rearrangement : TICdbCEP85L [6q22.31]  -  PDGFRB [6p21.32]
Rearrangement : TICdbERC1 [12p13.33]  -  PDGFRB [5q32]
Rearrangement : TICdbETV6 [12p13.2]  -  PDGFRB [11p13]
Rearrangement : TICdbGIT2 [12q24.11]  -  PDGFRB [3q27.3]
Rearrangement : TICdbGOLGA4 [3p22.2]  -  PDGFRB [3q27.3]
Rearrangement : TICdbHIP1 [7q11.23]  -  PDGFRB [9q22.2]
Rearrangement : TICdbNIN [14q22.1]  -  PDGFRB [2q31.1]
Rearrangement : TICdbPDE4DIP [1q21.1]  -  PDGFRB [11p13]
Rearrangement : TICdbPRKG2 [4q21.21]  -  PDGFRB [21q22.11]
Rearrangement : TICdbSPECC1 [17p11.2]  -  PDGFRB [12p13.31]
Rearrangement : TICdbTP53BP1 [15q15.3]  -  PDGFRB []
Rearrangement : TICdbTPM3 [1q21.3]  -  PDGFRB []
Rearrangement : TICdbTRIP11 [14q32.12]  -  PDGFRB []
Rearrangement : TICdbWDR48 [3p22.2]  -  PDGFRB []
Polymorphisms : SNP, variants
NCBI Variation ViewerPDGFRB [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)PDGFRB
dbVarPDGFRB
ClinVarPDGFRB
1000_GenomesPDGFRB 
Exome Variant ServerPDGFRB
SNP (GeneSNP Utah)PDGFRB
SNP : HGBasePDGFRB
Genetic variants : HAPMAPPDGFRB
Genomic VariantsPDGFRB  PDGFRB [DGVbeta]
Mutations
ICGC Data PortalENSG00000113721 
Cancer Gene: CensusPDGFRB 
Somatic Mutations in Cancer : COSMICPDGFRB 
CONAN: Copy Number AnalysisPDGFRB 
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] 
Diseases
DECIPHER (Syndromes)5:149493402-149535422
Mutations and Diseases : HGMDPDGFRB
OMIM131440    173410    213600    228550    615007   
MedgenPDGFRB
NextProtP09619 [Medical]
GENETestsPDGFRB
Disease Genetic AssociationPDGFRB
Huge Navigator PDGFRB [HugePedia]  PDGFRB [HugeCancerGEM]
snp3D : Map Gene to Disease5159
DGIdb (Drug Gene Interaction db)PDGFRB
General knowledge
Homologs : HomoloGenePDGFRB
Homology/Alignments : Family Browser (UCSC)PDGFRB
Phylogenetic Trees/Animal Genes : TreeFamPDGFRB
Chemical/Protein Interactions : CTD5159
Chemical/Pharm GKB GenePA33148
Clinical trialPDGFRB
Cancer Resource (Charite)ENSG00000113721
Other databases
Probes
Litterature
PubMed308 Pubmed reference(s) in Entrez
CoreMinePDGFRB
GoPubMedPDGFRB
iHOPPDGFRB

Bibliography

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
Golub TR, Barker GF, Lovett M, Gilliland DG
Cell. 1994 ; 77 (2) : 307-316.
PMID 8168137
 
Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution.
Abe A, Emi N, Tanimoto M, Terasaki H, Marunouchi T, Saito H
Blood. 1997 ; 90 (11) : 4271-4277.
PMID 9373237
 
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2).
Ross TS, Bernard OA, Berger R, Gilliland DG
Blood. 1998 ; 91 (12) : 4419-4426.
PMID 9616134
 
Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, Kaeda J, Cwynarski K, Goldman JM, Cross NC
Cancer research. 2000 ; 60 (13) : 3592-3598.
PMID 10910073
 
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.
Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE
Blood. 2001 ; 98 (8) : 2518-2525.
PMID 11588050
 
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).
Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, Williams IR, LaStarza R, Crescenzi B, Sternberg DW, Andreasson P, Schiavo R, Siena S, Mecucci C, Gilliland DG
Blood. 2001 ; 97 (12) : 3910-3918.
PMID 11389034
 
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM
The New England journal of medicine. 2002 ; 347 (7) : 481-487.
PMID 12181402
 
Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta.
Steer EJ, Cross NC
Acta haematologica. 2002 ; 107 (2) : 113-122.
PMID 11919393
 
Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, Testoni N, Hughes G, Salamanchuk Z, Calasanz MJ, Lahortiga I, Pocock CF, Dang R, Fidler C, Wainscoat JS, Boultwood J, Cross NC
British journal of haematology. 2003 ; 120 (2) : 251-256.
PMID 12542482
 
Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.
Garcia JL, Font de Mora J, Hernandez JM, Queizan JA, Gutierrez NC, Hernandez JM, San Miguel JF
Blood. 2003 ; 102 (7) : 2699-2700.
PMID 14504072
 
Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
Gunby RH, Cazzaniga G, Tassi E, Le Coutre P, Pogliani E, Specchia G, Biondi A, Gambacorti-Passerini C
Haematologica. 2003 ; 88 (4) : 408-415.
PMID 12681968
 
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.
Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, Aguiar RC
Blood. 2003 ; 102 (12) : 4187-4190.
PMID 12907457
 
p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
Grand FH, Burgstaller S, Kˆºhr T, Baxter EJ, Webersinke G, Thaler J, Chase AJ, Cross NC
Cancer research. 2004 ; 64 (20) : 7216-7219.
PMID 15492236
 
Oncogenic derivatives of platelet-derived growth factor receptors.
Jones AV, Cross NC
Cellular and molecular life sciences : CMLS. 2004 ; 61 (23) : 2912-2923.
PMID 15583853
 
HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2).
Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F, Maserati E, Pasquali F, Panarello C
Cancer research. 2004 ; 64 (8) : 2649-2651.
PMID 15087372
 
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
Vizmanos JL, Novo FJ, Romˆ°n JP, Baxter EJ, Lahortiga I, Larrˆ°yoz MJ, Odero MD, Giraldo P, Calasanz MJ, Cross NC
Cancer research. 2004 ; 64 (8) : 2673-2676.
PMID 15087377
 
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, DeAngelo DJ, Gilliland DG, Cools J
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 ; 19 (1) : 27-30.
PMID 15496975
 
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written07-2005José Luis Vizmanos

Citation

This paper should be referenced as such :
Vizmanos, JL
PDGFRB (platelet-derived growth factor receptor, beta polypeptide)
Atlas Genet Cytogenet Oncol Haematol. 2005;9(4):295-299.
Free online version   Free pdf version   [Bibliographic record ]
URL : http://AtlasGeneticsOncology.org/Genes/PDGFRBID21ch5q32.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sun Dec 21 03:20:26 CET 2014

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.